Cargando…
Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
INTRODUCTION: Drug reimbursement decisions are often made based on a price set by the manufacturer. In some cases, this price leads to public and scientific debates about whether its level can be justified in relation to its costs, including those related to research and development (R&D) and ma...
Autores principales: | Enzing, Joost J., Knies, Saskia, Engel, Jop, IJzerman, Maarten J., Sander, Beate, Vreman, Rick, Boer, Bert, Brouwer, Werner B. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434877/ https://www.ncbi.nlm.nih.gov/pubmed/36045377 http://dx.doi.org/10.1186/s12962-022-00383-y |
Ejemplares similares
-
Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride?
por: Enzing, Joost J., et al.
Publicado: (2021) -
Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries
por: Enzing, Joost J., et al.
Publicado: (2022) -
When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022) -
Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983) -
Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)